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Purpose: Studies on long-term sustainability of low-carbohydrate approaches to
treat diabetes are limited. We previously reported the effectiveness of a novel
digitally-monitored continuous care intervention (CCI) including nutritional ketosis in
improving weight, glycemic outcomes, lipid, and liver marker changes at 1 year. Here,
we assess the effects of the CCI at 2 years.
Materials and methods: An open label, non-randomized, controlled study with
262 and 87 participants with T2D were enrolled in the CCI and usual care (UC)
groups, respectively. Primary outcomes were retention, glycemic control, and weight
changes at 2 years. Secondary outcomes included changes in body composition, liver,
cardiovascular, kidney, thyroid and inflammatory markers, diabetes medication use and
disease status.
Results: Reductions from baseline to 2 years in the CCI group resulting from
intent-to-treat analyses included: HbA1c, fasting glucose, fasting insulin, weight, systolic
blood pressure, diastolic blood pressure, triglycerides, and liver alanine transaminase,
and HDL-C increased. Spine bone mineral density in the CCI group was unchanged.
Use of any glycemic control medication (excluding metformin) among CCI participants
declined (from 55.7 to 26.8%) including insulin (-62%) and sulfonylureas (-100%). The UC
group had no changes in these parameters (except uric acid and anion gap) or diabetes
medication use. There was also resolution of diabetes (reversal, 53.5%; remission,
17.6%) in the CCI group but not in UC. All the reported improvements had p < 0.00012.
Conclusion: The CCI group sustained long-term beneficial effects on multiple clinical
markers of diabetes and cardiometabolic health at 2 years while utilizing less medication.

Frontiers in Endocrinology | www.frontiersin.org

1

June 2019 | Volume 10 | Article 348

Athinarayanan et al.

Carbohydrate Restriction and Type 2 Diabetes

The intervention was also effective in the resolution of diabetes and visceral obesity with
no adverse effect on bone health.
Clinical Trial Registration: Clinicaltrials.gov NCT02519309
Keywords: type 2 diabetes, nutritional ketosis, HbA1c, body composition, reversal and remission

INTRODUCTION

control at 1 year (24). Systematic reviews also corroborate the
effectiveness of a low-carbohydrate diet for T2D (25, 26) and it
has recently become a consensus recommended dietary option
(27–29). Nonetheless, sustained adherence to carbohydrate
restriction is considered challenging (27, 28) and an LDL-C
increase is sometimes observed (30–33). Given that total LDLparticles (LDL-P), small LDL-P, and ApoB tend to improve or
remain unchanged, the impact of an increase in LDL-C on CVD
risk in the context of this dietary pattern is unknown.
We have previously reported 1 year outcomes of an openlabel, non-randomized, controlled, longitudinal study with 262
continuous care intervention (CCI), and 87 usual care (UC)
participants with T2D (10). The CCI included individualized
support with telemedicine, health coaching, and guidance in
nutritional ketosis using an individualized low-carbohydrate diet.
Nutritional guidance encouraged sustained nutritional ketosis;
patients were counseled on preparation of a low-carbohydrate
diet adapted to meet their life circumstances. Eighty-three
percent of CCI participants remained enrolled at 1 year and
60% of completers achieved an HbA1c <6.5% while prescribed
metformin or no diabetes medication. Weight was reduced and
most CVD risk factors improved (33).
Long-term studies of low-carbohydrate dietary approaches
to treat type 2 diabetes and obesity are limited, particularly
among those that are delivered and supported remotely. Here
we assess longer-term outcomes in CCI participants with T2D
at 2 years, as well as the effects on body composition and
related comorbidities. The primary aims were to investigate
the effect of the CCI on retention, glycemic control, diabetes
status, and weight. Secondary aims included: (1) investigating
the effect of the CCI on bone mineral density, visceral fat
composition, cardiovascular risk factors, liver, kidney, thyroid
and inflammatory markers, and related disease outcomes (e.g.,
metabolic syndrome); and (2) comparing 2-year outcomes
between the CCI and UC groups.

Type 2 diabetes (T2D), obesity, and metabolic disease impact
over one billion people and present a challenge to public health
and economic growth (1, 2). In the United States, over 30 million
people have diabetes and it is recognized among the leading
causes of morbidity and mortality, especially through increased
cardiovascular disease (CVD) (3). The remission rate under
usual care is 0.5–2% (4) while an intensive lifestyle intervention
resulted in remission rates (both partial and complete) of 11.5
and 9.2% at 1 and 2 years (5). When lifestyle interventions are
insufficient, medications are indicated to manage the disease and
slow progression (6, 7).
When T2D care directed at disease reversal is successful, this
includes achievement of restored metabolic health, glycemic
control with reduced dependence on medication, and in
some cases disease remission. Three non-pharmaceutical
approaches have demonstrated high rates of at least temporary
T2D diabetes reversal or remission: bariatric surgery, very
low calorie diets (VLCD), and nutritional ketosis achieved
through carbohydrate restriction (8–10). In controlled clinical
trials, each approach has demonstrated improved glycemic
control and CVD risk factors, reduced pharmaceutical
dependence, and weight loss. The three approaches show a
similar time-course with glycemic control preceding weight
loss by weeks or months, suggesting potential overlap of
mechanisms (11, 12).
With bariatric surgery, up to 60% of patients demonstrate T2D
remission at 1 year (13). Outcomes at 2 years and beyond indicate
∼50% of patients can achieve ongoing diabetes remission (13,
14). The second Diabetes Surgery Summit recommended using
bariatric surgery to treat T2D with support from worldwide
medical and scientific societies (15), but both complications
associated with surgery and cost limit its widespread use (16, 17).
VLCDs providing <900 kcal/day allow rapid discontinuation of
most medications, improved glycemic control, and weight loss.
This approach is necessarily temporary, however, with weight
regain and impaired glucose control typically occurring within 3–
6 months of reintroduction of substantial proportions of dietary
carbohydrates (9, 18–20).
A third approach to diabetes reversal is sustained dietary
carbohydrate restriction. Low-carbohydrate diets have
consistently elicited improvements in T2D, metabolic disease,
and obesity up to one year (21, 22), however, longer-term studies
and studies including patients prescribed insulin are limited.
A low-carbohydrate Mediterranean diet caused remission in
14.7% of newly diagnosed diabetes patients at 1 year vs. 4.1%
with a low-fat diet (23), and a small randomized trial utilizing
a ketogenic diet demonstrated improved weight and diabetes
Frontiers in Endocrinology | www.frontiersin.org

Abbreviations: CCI, continuous care intervention; UC, usual care; T2D, type
2 diabetes; HbA1c, hemoglobin A1c; CVD, cardiovascular disease; VLCD, very
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bone mineral density; CAF, central abdominal fat; A/G, android:gynoid ratio;
LELM, lower extremity lean mass; HDL, high density lipoprotein; LDL, low
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NAFLD, nonalcoholic fatty liver disease; NLF, NAFLD liver fat score; NFS, NAFLD
fibrosis score; TSH, thyroid stimulating hormone; BUN, blood urea nitrogen;
eGFR, estimated glomerular filtration rate; hsCRP, high sensitive C-reactive
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of Insulin Resistance; SGLT-2, sodium-glucose cotransporter-2 inhibitors; DPP4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like-peptide 1 receptor
agonists; FFM, fat-free mass; VAT, visceral adipose tissue; GLM, generalized linear
model; LMM, linear mixed-effect model; ADA, American Diabetes Association;

2

June 2019 | Volume 10 | Article 348

Athinarayanan et al.

Carbohydrate Restriction and Type 2 Diabetes

MATERIALS AND METHODS

CCI-virtual group received care and education primarily via appbased communication. The CCI-onsite group also received care
and education via clinic-based group meetings (weekly for 12
weeks, bi-weekly for 12 weeks, monthly for 6 months, and then
quarterly in the second year). All participants had access to the
app for communication with their care team, online resources,
biomarker tracking and the opportunity to participate in an
online peer community for social support.

Study Design and Participants
The comprehensive study design was previously published with
the 1 year outcomes (10, 33), and the results presented here
are the follow-up 2-year results from the same ongoing fiveyear clinical trial (Clinical trials.gov identifier: NCT02519309).
This is an open-label, non-randomized, outpatient study, and
results presented here are based on data from the first 2 years of
the trial collected from August, 2015 to May, 2018. Participants
aged 21 to 65 years with a confirmed diagnosis of T2D and
a body mass index (BMI) >25 kg/m2 self-selected to receive
either the CCI or usual care (UC). Major exclusion criteria are
listed in the previous publication (10, 33). All study participants
provided written informed consent and the study was approved
by the Franciscan Health Lafayette Institutional Review Board,
Lafayette, IN, USA.

Usual Care (UC)
The participants recruited for usual care (UC) received care
from their primary care physician or endocrinologist and were
counseled by a registered dietician as part of a diabetes education
program. These participants received the American Diabetes
Association (ADA) recommendations on nutrition, lifestyle and
diabetes management. No modification of their care was made
for the study and routine biomarkers (weight, glucose and
ketones) were not collected from these participants. This group
was used as a reference control to study the effect of disease
progression over 2 years in a cohort of participants prospectively
recruited from the same geography and healthcare system.
Figure 1 depicts the study flow from recruitment to 2 years
post-enrollment.

Study Interventions
Continuous Care Intervention (CCI)
For the intervention group, participants were advised to achieve
and sustain nutritional ketosis (blood BHB level of 0.5–3.0 mmol
L−1 ) through sufficient carbohydrate restriction (initially <30 g
day−1 but gradually increased based on personal carbohydrate
tolerance and health goals). Participants’ daily protein intake was
initially targeted at a level of 1.5 g kg−1 of a medium-frame ideal
weight body and further individualized based on biomarkers.
Participants were instructed to include sufficient dietary fat
in meals to achieve satiety without tracking energy intake.
Nutrition education directed consumption of monounsaturated
and saturated fat with sufficient intake of omega-3 and omega6 polyunsaturated fats. The participants were also encouraged to
consume sufficient fluid, vitamins and minerals including sodium
and magnesium, especially if signs of mineral deficiency were
encountered (e.g., decreased circulating volume) (10).
The CCI participants were provided access to a webbased software application (app), which was used to provide
telemedicine communication, online resources and biomarker
tracking tools. The participants used the app to upload and
monitor their reportable biomarkers including body weight,
blood glucose and beta-hydroxybutyrate (BHB). Biomarkers
allowed for daily feedback to the care team and individualization
of patient instruction. Frequency of reporting was personalized
over time based on care needs. The web-based app was also
used by participants to communicate with their remote care team
consisting of a health coach and a medical provider. The remote
care team provided education and support regarding dietary
changes, behavior modification techniques for maintenance of
lifestyle changes, and directed medication changes for diabetes
and antihypertensive medications. Education modules covered
core concepts related to the dietary changes for achieving
nutritional ketosis, and adaptation to and maintenance of the diet
(10). Participants selected their preferred education mode (CCIvirtual, n = 126 or CCI-onsite, n = 136) during recruitment. The

Outcomes
Primary Outcomes
The primary outcomes were retention, HbA1c, HOMAIR derived from insulin or c-peptide (formulas listed in
Supplementary Table 1), fasting glucose, fasting insulin, cpeptide and weight.

Secondary Outcomes
Long-term body composition changes assessed in CCI
participants included bone mineral density (BMD), abdominal
fat content (CAF and A/G ratioC), and lower extremity
lean mass (LELM). Body composition was not assessed in
UC participants. Cardiovascular-related markers included
resting blood pressure (systolic and diastolic), triglycerides,
total cholesterol, HDL-C and calculated LDL-C (Friedewald
equation, Supplementary Table 1). Liver-related markers
included the liver enzymes alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and alkaline phosphatase
(ALP), bilirubin, and two calculated liver scores: non-alcoholic
liver fat score (NLF) and non-alcoholic liver fibrosis score
(NFS) (formulas in Supplementary Table 1). Kidney-related
markers included serum creatinine, uric acid, anion gap, blood
urea nitrogen (BUN), and estimated glomerular filtration rate
(eGFR). Thyroid-related markers included thyroid stimulating
hormone (TSH) and free T4. Inflammatory markers included
high sensitive C-reactive protein (hsCRP) and white blood cell
count (WBC). Changes in overall diabetes medication use, use by
class, and insulin dose were tracked over the 2 years of the trial.
The prevalence and resolution of T2D (diabetes reversal,
partial and complete remission), metabolic syndrome, liver
steatosis, and fibrosis were evaluated at baseline and 2 years using
the criteria provided in Supplementary Table 2. Assignment of
metabolic syndrome was based on the presence of three of

CLIA, Clinical Laboratory Improvement Amendments; IRB, Institutional Review
Board; DXA, dual-energy X-ray absorptiometry.
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FIGURE 1 | Flow chart of participants in each stage of the study from recruitment to 2 years post-enrollment and analysis.

For assessment of fat mass, we manually selected the central
abdominal fat (CAF) region using the software and evaluated the
changes in CAF over time, as previously suggested for overweight
individuals (36, 39). Furthermore, we assessed changes in the
android:gynoid (A/G) ratio by time. Due to lack of proper arm
lean mass measurement, we analyzed the lower extremity lean
mass (LELM) to assess weight-related changes in lean mass over
time (40, 41).

the five defined criteria according to measured laboratory and
anthropometric variables (34, 35) and pharmacological treatment
for any of the conditions was not considered in the assignment
(Supplementary Table 2).
Adverse events encountered in the study were reported to the
Principal Investigator and reviewed by the Institutional Review
Board (IRB).

Laboratory Measures
Statistical Analyses

Clinical anthropometrics and laboratory blood analyte
measurements were obtained at baseline, 1 year, and 2 years
from the CCI and UC participants. Details of the methods were
previously published (10). All blood analytes were measured
at a Clinical Laboratory Improvement Amendments (CLIA)
certified laboratory.

All analyses were conducted using SPSS statistical software
(Version 25.0, Armonk, NY). First, we examined the assumptions
of normality and linearity. According to Kline’s (2011) guidelines
(42), 14 outcomes (i.e., fasting insulin, insulin and C-peptidederived HOMA-IR scores, triglycerides, ALT, AST, bilirubin,
N-LFS, BUN, serum creatinine, TSH, Free T4, hsCRP, and
BHB) were positively skewed. We explored two approaches to
handling the skewed variables: natural log-transformations and
removing the top 1% of values. For N-LFS, which includes both
positive and negative values, a modulus log-transformation was
performed instead of a natural log-transformation (43). For most
variables, both approaches resulted in new skew and kurtosis
values within the acceptable range. One variable (triglycerides)
was only corrected via log-transformation, whereas two variables
(C-peptide-derived HOMA-IR and TSH) were only corrected
by removing the top 1% of values. For the other variables, we
conducted sensitivity analyses to compare the two approaches.
Because the results did not differ between the approaches
and because interpretation of outcomes is more difficult with
transformed variables, we report results from the approach
of removing the top 1% of values for all variables except

Body Composition Measures
The CCI participants’ total body composition was measured
at baseline, 1 year and 2 years using dual-energy X-ray
absorptiometry (DXA) (Lunar GE Prodigy, Madison, WI).
Participants were scanned while wearing light clothing using
standard clinical imaging procedures. The scans obtained were
analyzed using GE Encore software (v11.10, Madison, WI).
In many obese patients, full body scans were not obtained
due to the scanner not accommodating the patient’s complete
body resulting in issues such as cropping of the arms and/or
overlapping of arms with the chest (36, 37). To address these
limitations, changes in bone density and fat and lean mass were
assessed using subregions rather than the full body scan. We
assessed changes in the bone mass by evaluating total spine
bone mineral density (BMD) from baseline to 2 years (38).
Frontiers in Endocrinology | www.frontiersin.org

4

June 2019 | Volume 10 | Article 348

Athinarayanan et al.

Carbohydrate Restriction and Type 2 Diabetes

TABLE 1 | Baseline characteristics.
All

Completers with data

Dropout or missing data

CompletersDropouts

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

Mean ±
SE

CCI-all education

262

53.8 (8.4)

194

54.4 (8.2)

68

51.9 (8.7)

2.5 ± 1.2

Usual Care

87

52.3 (9.5)

68

51.4 (9.4)

19

55.6 (9.5)

−4.2 ± 2.4

Age (years)

CCI-all vs. usual care

1.4 ± 1.1

3.0 ± 1.2

−3.6 ± 2.4

African American (%)
CCI-all education

262

6.9 ± 1.6

194

6.2 ± 1.7

68

8.8 ± 3.5

−2.6 ± 3.6

Usual Care

87

0.0 ± 0.0

68

0.0 ± 0.0

19

0.0 ± 0.0

—

CCI-all vs. usual care

6.9 ± 1.6*

6.2 ± 1.7*

8.8 ± 3.5

Body mass index (kg m−2 )
CCI-all education

257

40.42 (8.81)

190

40.41 (8.42)

67

40.46 (9.90)

−0.05 ± 1.25

Usual Care

83

36.72 (7.26)

64

36.90 (7.41)

19

36.11 (6.89)

0.79 ± 1.91

CCI-all vs. usual care

3.70 ± 1.07*

3.51 ± 1.18

4.34 ± 2.43

Female (%)
CCI-all education

262

66.79 ± 2.92

194

65.98 ± 3.41

68

69.12 ± 5.64

−3.14 ± 6.66

Usual Care

87

58.62 ± 5.31

68

60.29 ± 5.98

19

52.63 ± 11.77

7.66 ± 12.90

CCI-all vs. usual care

8.17 ± 6.06

5.69 ± 6.76

16.49 ± 12.35

Waist circumference (in)
CCI-all education

218

49.02 (5.64)

159

49.04 (6.40)

59

48.97 (6.89)

0.06 ± 1.00

Usual Care

83

46.41 (5.64)

64

46.33 (5.63)

19

46.67 (5.82)

0.34 ± 1.48

CCI-all vs. usual care

2.61 ± 0.81

2.71 ± 0.92

2.30 ± 1.75

Years since type 2 diabetes diagnosis
CCI-all education

261

8.44 (7.22)

193

8.15 (7.02)

68

9.25 (7.75)

−1.1 ± 1.02

Usual Care

71

7.85 (7.32)

63

7.90 (7.41)

8

7.38 (7.05)

0.53 ± 2.77

CCI-all vs. usual care

0.59 ± 0.97

0.25 ± 1.03

1.88 ± 2.87

GLYCEMIC
Hemoglobin A1c (%)
CCI-all education

262

7.6 (1.5)

194

7.5 (1.41)

68

7.9 (1.7)

−0.4 ± 0.2

Usual Care

87

7.6 (1.8)

68

7.7 (1.9)

19

7.41 (1.4)

0.3 ± 0.5

CCI-all vs. usual care

−0.0 ± 0.2

−0.2 (0.3)

0.45 ± 0.43

C-Peptide (nmol L−1 )
CCI-all education

248

4.36 (2.15)

185

4.40 (2.15)

63

4.25 (2.17)

0.15 ± 0.31

Usual Care

79

4.18 (2.48)

62

3.86 (2.22)

17

5.35 (3.08)

−1.50 ± 0.80

CCI-all vs. usual care

0.18 ± 0.29

0.54 ± 0.32

−1.10 ± 0.80

Fasting glucose (mg/dL)
CCI-all education

258

160.77 (61.37)

191

158.01 (60.77)

67

168.64 (62.86)

−10.63 ± 8.81

Usual Care

86

156.20 (72.60)

67

162.07 (78.71)

19

135.47 (39.85)

26.60 ± 13.27

CCI-all vs. usual care

4.57 ± 8.01

−4.06 ± 10.57

33.17 ± 15.25

Fasting Insulin (mIU L−1 )
CCI-all education

248

28.56 (23.88)

185

27.37 (22.33)

63

32.06 (27.86)

−4.70 ± 3.87

Usual Care

79

29.11 (24.85)

62

25.54 (21.87)

17

42.12 (30.95)

−16.58 ± 6.58

CCI-all vs. usual care

−0.55 ± 3.12

1.83 ± 3.26

−10.05 ± 7.79

HOMA-IR (insulin derived), all
CCI-all education

220

8.96 (6.17)

168

8.92 (6.19)

52

9.10 (6.14)

−0.19 ± 0.98

Usual Care

78

10.64 (9.12)

61

9.56 (8.35)

17

14.52 (10.88)

−4.96 ± 2.85

CCI-all vs. usual care

−1.68 ± 1.11

−0.65 ± 1.17

−5.41 ± 2.77

HOMA-IR (insulin derived), excluding exogenous users
CCI-all education

157

8.80 (5.64)

121

8.62 (5.74)

36

9.41 (5.31)

−0.78 ± 1.07

Usual Care

42

9.41 (8.35)

32

7.95 (6.53)

10

14.09 (11.77)

−6.15 ± 2.90

CCI-all vs. usual care

−0.61 ± 1.36

0.68 ± 1.17

−4.68 ± 3.82
(Continued)
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TABLE 1 | Continued
All

N

Completers with data

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

Dropout or missing data

N

CompletersDropouts

Mean (SD)
or ± SE

Mean ±
SE

HOMA-IR (C-peptide derived), all
CCI-all education

244

11.73 (7.40)

182

11.52 (6.55)

62

12.33 (9.51)

−0.80 ± 1.09

Usual Care

78

11.10 (7.56)

61

10.63 (7.64)

17

12.80 (7.23)

−2.17 ± 2.07

CCI-all vs. usual care

0.62 ± 0.97

0.89 ± 1.01

−0.47 ± 2.49

METABOLIC AND BODY COMPOSITION
Diabetes reversal (%)a
CCI-all education

262

12.2 ± 2.0

194

12.9 ± 2.4

68

10.3 ± 3.7

2.6 ± 4.6

Usual Care

87

20.7 ± 4.4

68

19.1 ± 4.8

19

26.3 ± 10.4

−7.2 ± 10.6

CCI-all vs. usual care

−8.5 ± 4.8

−6.2 ± 5.4

−16.0 ± 11.0

Metabolic syndrome (%)
CCI-all education

262

88.6 ± 2.0

194

88.7 ± 2.3

68

88.2 ± 4.0

0.4 ± 4.5

Usual Care

81

91.4 ± 3.1

62

93.6 ± 3.2

19

84.2 ± 9.0

9.3 ± 9.2

CCI-all vs. usual care

−2.8 ± 4.0

−4.9 ± 3.9

4.0 ± 8.7

Weight-clinic (kgs)
CCI-all education

257

116.50 (25.94)

190

115.97 (24.94)

67

117.98 (28.72)

−2.00 ± 3.69

Usual Care

83

105.63 (22.14)

64

105.32 (21.81)

19

106.67 (23.82)

−1.35 ± 5.82

CCI-all vs. usual care

10.87 ± 3.17*

10.65 ± 3.50

11.32 ± 7.21

Spine bone mineral density (g/cm2 )
CCI-all education

238

1.20 (0.16)

178

1.20 (0.15)

60

1.21 (0.18)

−0.01 ± 0.03

237

5.77 (1.69)

177

5.72 (1.69)

60

5.94 (1.72)

−0.22 ± 0.25

238

1.27 (0.33)

178

1.26 (0.33)

60

1.31 (0.34)

−0.06 ± 0.05

238

18.45 (4.05)

178

18.42 (3.94)

60

18.53 (4.40)

−0.11 ± 0.61

Central abdominal fat (kg)
CCI-all education
Android: gynoid ratio
CCI-all education
Lower extremity lean mass (kg)
CCI-all education
CARDIOVASCULAR
Systolic blood pressure (mmHg)
CCI-all education

260

131.9 (14.1)

192

132.2 (14.2)

68

131.1 (13.8)

1.2 (2.0)

Usual Care

79

129.8 (13.6)

61

129.0 (13.6)

18

132.7 (13.5)

−3.7 (3.7)

CCI-all vs. usual care

2.1 ± 1.8

3.3 ± 2.1

−1.6 ± 3.6

Diastolic blood pressure (mmHg)
CCI-all education

260

82.1 (8.3)

192

81.7 (8.0)

68

83.4 (8.9)

−1.7 ± 1.2

Usual Care

79

82.0 (8.9)

61

82.1 (8.8)

18

81.8 (9.6)

0.3 ± 2.4

CCI-all vs. usual care

0.1 ± 1.1

−0.4 ± 1.2

1.6 ± 2.4

Total cholesterol (mg/dL)
CCI-all education

247

183.6 (41.2)

184

181.9 (40.3)

63

188.7 (43.6)

−6.8 ± 6.0

Usual Care

79

183.8 (45.8)

62

186.5 (49.3)

17

174.0 (28.7)

12.5 ± 12.5

CCI-all vs. usual care

−0.2 ± 5.5

−4.6 ± 6.3

14.7 ± 11.2

LDL-cholesterol (mg/dL)
CCI-all education

232

102.5 (32.9)

173

101.1 (33.0)

59

106.6 (32.6)

−5.5 ± 5.0

Usual Care

70

101.5 (36.2)

56

103.8 (38.3)

14

92.3 (24.8)

11.5 ± 10.8

CCI-all vs. usual care

1.0 ± 4.6

−2.7 ± 5.3

14.3 ± 9.3

HDL-cholesterol (mg/dL)
CCI-all education

247

42.2 (13.4)

184

42.5 (13.7)

63

41.3 (12.7)

1.1 ± 2.0

Usual Care

79

37.6 (11.2)

62

38.3 (11.5)

17

35.2 (10.1)

3.0 ± 3.1

CCI-all vs. usual care

4.6 ± 1.7

4.2 ± 1.9

6.1 ± 3.3
(Continued)
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TABLE 1 | Continued
All

N

Completers with data

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

Dropout or missing data

N

CompletersDropouts

Mean (SD)
or ± SE

Mean ±
SE

Triglycerides (mg/dL)
CCI-all education

247

197.2 (143.4)

184

200.7 (153.5)

63

187.1 (109.0)

13.5 ± 21.0

Usual Care

79

282.9 (401.2)

62

283.7 (443.6)

17

280.0 (185.0)

3.7 ± 110.5

CCI-all vs. usual care

−85.7 ± 46.1

−83.0 ± 57.5

−92.9 ± 46.9

LIVER
ALT (Units/L)
CCI-all education

257

30.65 (22.77)

190

31.65 (24.54)

67

27.79 (16.63)

3.86 ± 3.23

Usual Care

86

27.74 (19.81)

67

28.31 (21.30)

19

25.74 (13.59)

2.58 ± 5.17

CCI-all vs. usual care

2.90 ± 2.75

3.34 ± 3.38

2.05 ± 4.17

AST (Units/L)
CCI-all education

257

23.69 (15.19)

190

24.37 (16.79)

67

21.76 (9.08)

2.61 ± 2.16

Usual Care

86

23.90 (19.39)

67

24.25 (21.36)

19

22.63 (10.02)

1.62 ± 5.07

CCI-all vs. usual care

−0.20 ± 2.04

0.12 ± 2.57

−0.87 ± 2.42

ALP (Units/L)
CCI-all education

256

74.11 (22.14)

189

74.32 (22.32)

67

73.54 (21.79)

0.78 ± 3.15

Usual Care

86

77.36 (26.29)

67

78.25 (27.67)

19

74.21 (21.08)

4.04 ± 6.86

CCI-all vs. usual care

−3.25 ± 2.90

−3.94 ± 3.39

−0.67 ± 5.62

Bilirubin (mg/dL)
CCI-all education

256

0.54 (0.21)

189

0.55 (0.21)

67

0.49 (0.18)

0.06 ± 0.03

Usual Care

86

0.55 (0.28)

67

0.54 (0.27)

19

0.59 (0.29)

−0.05 ± 0.07

CCI-all vs. usual care

−0.02 ± 0.03

0.01 ± 0.04

−0.11 ± 0.05

NAFLD-Liver fat score
CCI-all education

243

3.43 (3.84)

181

3.26 (3.62)

62

3.92 (4.44)

−0.65 ± 0.62

Usual Care

74

3.10 (3.63)

57

2.49 (3.00)

17

5.14 (4.80)

−2.65 ± 1.23

CCI-all vs. usual care

0.33 ± 0.50

0.78 ± 0.53

−1.23 ± 1.24

NAFLD-Fibrosis score
CCI-all education

238

−0.23 (1.36)

177

−0.25 (1.37)

61

−0.18 (1.35)

−0.07 ± 0.20

Usual Care

75

−0.80 (1.41)

58

−0.82 (1.47)

17

−0.71 (1.20)

−0.11 ± 0.39

CCI-all vs. usual care

0.56 ± 0.18

0.57 ± 0.21

0.53 ± 0.36

KIDNEY
Anion gap (mmol L−1 )
CCI-all education

257

6.83 (1.67)

190

6.76 (1.68)

67

7.03 (1.62)

−0.27 ± 0.24

Usual Care

86

6.93 (1.82)

67

6.82 (1.86)

19

7.32 (1.67)

−0.50 ± 0.47

CCI-all vs. usual care

−0.10 ± 0.21

−0.06 ± 0.25

−0.29 ± 0.42

BUN (mg/dL)
CCI-all education

258

16.88 (6.55)

191

17.17 (6.05)

67

16.06 (7.81)

1.11 ± 0.93

Usual Care

86

16.05 (6.25)

67

15.81 (6.28)

19

16.89 (6.24)

−1.09 ± 1.63

CCI-all vs. usual care
eGFR (mL s−1 m−2 )

0.84 ± −0.81

1.37 ± 0.87

−0.84 ± 1.95

258

80.48 (13.62)

191

80.36 (13.53)

67

80.84 (13.96)

−0.48 ± 1.94

86

79.17 (13.73)

67

79.39 (13.72)

19

78.42 (14.11)

0.97 ± 3.59

CCI-all education
Usual Care
CCI-all vs. usual care

1.31 ± 1.70

0.97 ± 1.93

2.42 ± 3.64

Serum creatinine (mg/dL)
CCI-all education

258

0.88 (0.24)

191

0.88 (0.23)

67

0.90 (0.26)

−0.02 ± 0.03

Usual Care

86

0.91 (0.25)

67

0.91 (0.25)

19

0.90 (0.22)

0.004 ± 0.06

CCI-all vs. usual care

−0.02 ± 0.03

−0.03 ± 0.03

−0.01 ± 0.07
(Continued)
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TABLE 1 | Continued
All

Completers with data

Dropout or missing data

CompletersDropouts

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

Mean ±
SE

CCI-all education

261

5.85 (1.46)

193

5.88 (1.45)

68

5.77 (1.48)

0.11 ± 0.21

Usual Care

85

5.60 (1.47)

67

5.58 (1.34)

18

5.70 (1.92)

0.12 ± 0.39

Uric acid (mg/dL)

CCI-all vs. usual care

0.25 ± 0.18

0.30 ± 0.20

0.07 ± 0.42

THYROID
TSH (mIU L−1 )
CCI-all education

259

2.32 (1.74)

192

2.31 (1.81)

67

2.36 (1.52)

−0.05 ± 0.25

Usual Care

86

3.80 (17.07)

68

4.37 (19.17)

18

1.65 (1.05)

2.72 ± 4.54

CCI-all vs. usual care

−1.48 ± 1.84

−2.06 ± 2.33

0.71 ± 0.38

Free T4 (ng/dL)
CCI-all education

260

0.92 (0.17)

193

0.92 (0.18)

67

0.91 (0.17)

0.01 ± 0.02

Usual Care

86

0.88 (0.29)

68

0.87 (0.31)

18

0.89 (0.16)

−0.02 ± 0.08

CCI-all vs. usual care

0.04 ± 0.03

0.05 ± 0.03

0.02 ± 0.04

OTHER
Beta-hydroxybutyrate (mmol L−1 )
CCI-all education

248

0.17 (0.15)

185

0.17 (0.15)

63

0.19 (0.16)

−0.03 ± 0.02

Usual Care

79

0.15 (0.13)

62

0.14 (0.11)

17

0.20 (0.18)

−0.06 ± 0.04

CCI-all vs. usual care

0.02 ± 0.20

0.03 ± 0.18

−0.01 (0.04)

hsC-reactive protein (nmol L−1 )
CCI-all education

249

8.54 (14.49)

186

8.92 (16.35)

63

7.44 (6.41)

1.48 ± 2.12

Usual Care

85

8.89 (8.62)

67

9.08 (8.91)

18

8.18 (7.64)

0.90 ± 2.30

CCI-all vs. usual care

−0.34 ± 1.67

−0.16 ± 2.10

−0.74 ± 1.79

White blood cell (k/cumm)
CCI-all education

260

7.24 (1.89)

193

7.12 (1.82)

67

7.57 (2.08)

−0.45 ± 0.27

Usual Care

86

8.14 (2.39)

67

8.15 (2.30)

19

8.08 (2.73)

0.07 ± 0.62

CCI-all vs. usual care

−0.90 ± 0.28

−1.03 ± 0.31*

−0.51 ± 0.58

DIABETES MEDICATION
Any diabetes medication, excluding metformin (%)
CCI-all education

262

56.87 ± 3.07

194

55.67 ± 3.58

68

60.29 ± 5.98

−4.62 ± 7.00

Usual Care

87

66.67 ± 5.08

68

66.18 ± 5.78

19

68.42 ± 10.96

−2.25 ± 12.37

CCI-all vs. usual care

−9.80 ± 5.94

−10.51 ± 6.80

−8.13 ± 12.71

Sulfonylurea (%)
CCI-all education

262

23.66 ± 2.63

194

25.77 ± 3.15

68

17.65 ± 4.66

8.13 ± 5.62

Usual Care

87

24.14 ± 4.61

68

22.06 ± 5.07

19

31.58 ± 10.96

−9.52 ± 11.19

CCI-all vs. usual care

−0.47 ± 5.28

3.71 ± 6.11

−13.93 ± 11.91

Insulin (%)
CCI-all education

262

29.77 ± 2.83

194

29.38 ± 3.28

68

30.88 ± 5.64

−1.50 ± 6.47

Usual Care

87

45.98 ± 5.37

68

48.53 ± 6.11

19

36.84 ± 11.37

11.69 ± 12.91

CCI-all vs. usual care

−16.21 ± 6.07

−19.15 ± 6.93

−5.96 ± 12.25

Thiazolidinedione (%)
CCI-all education

262

1.53 ± 0.76

194

1.55 ± 0.89

68

1.47 ± 01.47

0.08 ± 1.74

Usual Care

87

1.15 ± 1.15

68

1.47 ± 1.47

19

0.00 ± 0.00

1.47 ± 2.79

CCI-all vs. usual care

0.38 ± 1.48

0.08 ± 1.74

1.47 ± 2.79

SGLT-2 (%)
CCI-all education

262

10.31 ± 1.88

194

9.79 ± 2.14

68

11.77 ± 3.94

−1.97 ± 4.30

Usual Care

87

14.94 ± 3.84

68

14.71 ± 4.33

19

15.79 ± 8.59

−1.08 ± 9.36

CCI-all vs. usual care

−4.64 ± 4.28

−4.91 ± 4.83

−4.03 ± 8.71
(Continued)
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TABLE 1 | Continued
All

Completers with data

Dropout or missing data

CompletersDropouts

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

N

Mean (SD)
or ± SE

Mean ±
SE

CCI-all education

262

9.92 ± 1.85

194

9.28 ± 2.09

68

11.77 ± 3.94

−2.49 ± 4.23

Usual Care

87

8.05 ± 2.93

68

5.88 ± 2.87

19

15.79 ± 8.59

−9.91 ± 9.06

DPP-4 (%)

CCI-all vs. usual care

1.88 ± 3.63

3.40 ± 3.92

−4.03 ± 8.71

GLP-1 (%)
CCI-all education

262

13.36 ± 2.11

194

13.40 ± 2.45

68

13.24 ± 4.14

0.17 ± 4.81

Usual Care

87

16.09 ± 3.96

68

19.12 ± 4.80

19

5.26 ± 5.26

13.85 ± 7.13

CCI-all vs. usual care

−2.73 ± 4.31

−5.72 ± 5.39

7.97 ± 8.33

Metformin (%)
CCI-all education

262

71.37 ± 2.80

194

71.65 ± 3.24

68

70.59 ± 05.57

1.06 ± 6.39

Usual Care

87

60.92 ± 5.26

68

60.29 ± 5.98

19

63.16 ± 11.37

−2.86 ± 12.81

CCI-all vs. usual care

10.46 ± 5.96

11.36 ± 6.80

7.43 ± 12.12

SD, standard deviation; SE, standard error; CCI, continuous care intervention; UC, usual care; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; BUN,
blood urea nitrogen; eGFR, estimated glomerular filtration rates; TSH, thyroid stimulating hormone; SGLT-2, Sodium glucose co-transporter 2 inhibitor; DPP-4, Dipeptidyl peptidase-4
inhibitor; GLP-1, Glucagon-like peptide 1 receptor agonist.
Ns slightly differs for each variable depending on the patients’ compliance to complete their laboratory, body composition assessments and clinic visits within the specified time-frame.
a Meeting diabetes reversal criteria at baseline was defined as HbA1c <6.5% and no use of medication for glycemic control other than metformin.
* A significance level of P < 0.0012 ensures overall simultaneous significance of P < 0.05 over the 43 variables using Bonferroni correction.

We also examined changes in participants’ diabetes
medication use. First, we compared the rates of diabetes
medication use within groups from baseline to 2 years using
McNemar’s test with continuity correction when appropriate.
Next, we calculated the proportion of participants in each group
with each diabetes medication class eliminated, reduced, not
changed, increased, or added. Paired t-tests were used to assess
within-group changes in insulin dosages from baseline to 2
years among participants taking insulin at baseline and among
participants taking insulin at both baseline and 2 years.
We conducted a second set of analyses with 2-year
completers only. Results of the completers-only analyses appear
in Supplementary Table 3. Given that 2 different modes (virtual
and onsite) were utilized for delivery of the CCI group
educational content, we also conducted another set of analyses
to assess whether differences existed between the groups on
all analyses of primary outcomes. As in our prior time points
(10, 48), no group differences were found; thus, the data from the
two CCI educational groups were combined for this report. For
all study analyses, nominal significance levels (P) are presented
in the tables. A significance level of P < 0.0012 ensures overall
simultaneous significance of P < 0.05 over the 43 variables using
Bonferroni correction.

triglycerides. For triglycerides, analyses were performed and
p-values reported on the log-transformed variable but the
means and standard errors reported were computed from the
untransformed variable. Next, we ran independent sample t-tests
to examine differences in baseline characteristics between CCI
and UC, and completers and dropouts.
We performed linear mixed-effects models (LMMs) to assess
(1) within-group changes in the continuous study outcomes
from baseline to 2 years and (2) between-group differences
(CCI vs. UC) in the study outcomes at 2 years. The LMMs
included fixed effects for time, group (CCI vs. UC), and a
time by group interaction. Covariates included baseline age, sex,
race (African American vs. other), BMI, and insulin use. This
maximum likelihood-based approach uses all available repeated
data, resulting in an intent-to-treat analysis. An unstructured
covariance structure was specified for all models to account for
correlations between repeated measures.
Within-group changes and between-group differences in
dichotomous disease outcome variables [i.e., diabetes reversal,
diabetes remission (partial or complete) and complete remission
(44), metabolic syndrome (34, 35), steatosis (45), fibrosis (46)]
were assessed, controlling for baseline age, sex, race, time since
diagnosis, BMI, and insulin use. For this set of analyses, multiple
imputation was used to replace missing values from baseline and
2 years with a set of plausible values, facilitating an intent-to-treat
analysis (all ns = 262). Missing values were estimated from 40
imputations (47) from logistic regression. Within-group changes
from baseline to 2 years and between-group differences at 2 years
were assessed using generalized estimating equations with binary
logistic models and unstructured covariance matrices.
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Participant Characteristics
Table 1 presents baseline characteristics of the 262 CCI and 87
UC participants. Participants did not differ between groups in
demographic characteristics, except the proportion of African
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Complete remission was observed in 17 (6.7%) CCI participants
and none (0%) of the UC participants at 2 years.

Americans was higher in the CCI group. Baseline characteristics
were well-matched between the groups, except for mean weight
and BMI, which were higher in the CCI group. There were
no differences between completers and dropouts on baseline
characteristics for either group.

Weight and Body Composition Outcomes
At 2 years, the mean weight reduction from baseline was
−10% (Figure 4A) in the CCI group, whereas no change was
observed in the UC group (Supplementary Figure 1C). Among
CCI patients, 74% had ≥5% weight loss compared to only 14%
of UC patients (Supplementary Figure 2; completers analysis, n
= 193). Consistent with the weight loss observed, the CCI group
had reductions in abdominal fat content with decreases in CAF
(Figure 4B) and the A/G ratio from baseline to 2 years (Table 2).
Total spine BMD within the CCI remained unchanged from
baseline to 2 years after correction for multiple comparisons,
whereas the average LELM was reduced from baseline to 2
years (Table 2).

Retention and Long-Term
Dietary Adherence
One hundred ninety four participants (74% of 262) remained
enrolled in the CCI at 2 years (Figure 1), as did 68 UC
group participants (78% of 87). CCI-participant-reported reasons
for dropout included: intervening life events (e.g., family
emergencies), difficulty attending or completing laboratory and
clinic visits associated with the trial, and insufficient motivation
for participation in the intervention. At both 1 and 2 years,
laboratory-measured blood BHB was 0.27 ± 0.02 mmol L−1 , 50%
higher than the baseline value (0.18 ± 0.01 mmol L−1 ). The mean
laboratory BHB level was stable from 1 to 2 years, and 61.5% (n
= 161) of participants uploaded a blood BHB measurement >0.5
mmol L−1 in the app at least once between 1 and 2 years.

Cardiovascular Risk Factor Outcomes
Decreases in systolic (Figure 4C) and diastolic (Figure 4D) blood
pressures and triglycerides were observed in the CCI but not
UC group at 2 years (Table 2; Supplementary Figures 3A,B).
The CCI group’s HDL-cholesterol and LDL-cholesterol both
increased from baseline to 2 years, whereas no changes were
observed in the UC group (Table 2). No changes in total
cholesterol were observed in either the CCI or UC group. At 2
years, the CCI group had higher HDL-cholesterol, higher LDLcholesterol, and lower triglycerides than UC. No between-group
differences were observed at 2 years in systolic or diastolic blood
pressure or total cholesterol (Table 2).

Glycemic Control
HbA1c improved at 2 years (0.9% unit decrease, P = 1.8 ×
10−17 ; Figure 2A) among CCI participants and was lower than
the UC group. Related markers including C-peptide, fasting
glucose, fasting insulin (Figure 2B), insulin-derived HOMAIR excluding exogenous insulin users, and c-peptide-derived
HOMA-IR also significantly decreased after correction for
multiple comparisons in the CCI group at 2 years and were
lower than the UC group (except C-peptide); no changes
from baseline to 2 years were observed in the UC group
(Supplementary Figures 1A,B; Table 2).
Within the CCI, reduction in glycemia occurred concurrently
with reduced medication use (Supplementary Table 3). The
proportion of CCI completers taking any diabetes medication
(excluding metformin) decreased at 2 years (Figure 3A). The
mean dose among CCI participants prescribed insulin at baseline
decreased by 81% at 2 years (from 81.9 to 15.5 U/day), but
not among UC participants (+13%; from 96.6 to 109.3 U/day)
(Figure 3B). For participants who remained insulin-users at 2
years, mean dose also decreased in the CCI by 61% (from 104.3
to 40.2 U/day, P = 9.2 × 10−5 ) but not in UC participants
(+19% from 103.8 to 123.5 U/day, P = 0.29). Among completers
prescribed each diabetes medication class, the proportion with
each dosage change (eliminated, reduced, unchanged, increased
or newly added) at 2 years in each group appears in Figure 3C.

Liver-Related Outcomes
Reductions were observed in liver-related outcomes including
ALT (Figure 4E), AST, ALP, NLF and NFS in the CCI group,
whereas no changes were observed in the UC group (Table 2,
e.g., ALT; Supplementary Figure 3C). No Bonferroni-corrected
group differences were observed for bilirubin, ALT, or AST at 2
years (Table 2).

Kidney, Thyroid, and
Inflammation Outcomes
The eGFR increased in the CCI but not UC group at 2 years
(Table 2). The UC but not CCI group had increased anion
gap and decreased uric acid. No bonferroni-corrected withingroup changes in BUN, serum creatinine, TSH, or Free T4 were
observed in either the CCI or UC group from baseline to 2 years.
No between-group differences were observed for any thyroid- or
kidney-related markers at 2 years (Table 2).
From baseline to 2 years, decreases in the CCI group’s hsCRP
(Figure 4F) and white blood cells were observed. No changes
were observed in the UC group (Supplementary Figure 3D). At
2 years, both markers of inflammation were lower in the CCI
group compared to the UC group (Table 2).

Diabetes Status
All within-group changes and between-group differences in
diabetes status among the CCI and UC group participants
appear in Supplementary Table 4 (intent-to-treat analyses were
conducted, all below ns = 262). The proportion of participants
meeting the defined criteria for diabetes reversal at 2 years
increased to 53.5% from baseline in the CCI group, whereas
no change was observed in the UC group. Diabetes remission
(partial or complete) was observed in 46 (17.6%) participants in
the CCI group and two (2.4%) of the UC participants at 2 years.
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All within-group changes and between-group differences in
comorbidities status among the CCI and UC group participants
appear in Supplementary Table 4 (intent-to-treat analyses were
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GLYCEMIC

0.2 ± 0.2

CCI-all vs. usual care
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4.39 ± 0.24

−0.06 ± 0.28

Usual Care

CCI-all vs. usual care

151.21 ± 6.93

12.47 ± 8.02

Usual Care

CCI-all vs. usual care

11

27.57 ± 2.29

0.16 ± 2.63

Usual Care

CCI-all vs. usual care

−0.49 ± 0.85

CCI-all vs. usual care

0.57

0.95

0.12

0.84

0.28

P

8.66 ± 0.92

0.43 ± 1.03

Usual Care

CCI-all vs. usual care

11.04 ± 0.67

0.21 ± 0.77

Usual Care

CCI-all vs. usual care

3.49 ± 1.27

111.07 ± 1.09

Usual Care

CCI-all vs. usual care

114.56 ± 0.60

CCI-all education

Weight-clinic (kg)

METABOLIC AND BODY COMPOSITION

11.25 ± 0.37

CCI-all education

HOMA-IR (C-peptide derived), alla

9.08 ± 0.46

CCI-all education

0.01

0.78

HOMA-IR (insulin derived), excluding exogenous usersa

9.09 ± 0.41

9.58 ± 0.73

CCI-all education

Usual Care

HOMA-IR (insulin derived), alla

27.73 ± 1.26

CCI-all education

Fasting Insulin (mIU L−1 )a

163.67 ± 3.90

CCI-all education

Fasting glucose (mg/dL)

4.33 ± 0.13

CCI-all education

C-Peptide (nmol L−1 )

7.7 ± 0.1

7.5 ± 0.2

CCI-all education

Usual Care

Hemoglobin A1c (%)

Mean ± SE

Baseline

TABLE 2 | Adjusted mean changes over time.

−11.44 ± 1.71

111.71 ± 1.47

100.27 ± 0.86

−3.75 ± 0.81

11.81 ± 0.71

8.07 ± 0.38

−6.31 ± 1.08

10.87 ± 0.98

4.56 ± 0.44

−5.48 ± 0.84

10.33 ± 0.73

4.85 ± 0.39

−10.00 ± 2.38

26.47 ± 2.06

16.47 ± 1.13

−33.30 ± 7.24

160.58 ± 6.17

127.29 ± 3.62

−1.12 ± 0.28

4.38 ± 0.25

3.27 ± 0.14

−1.3 ± 0.2

7.6 ± 0.1

6.3 ± 0.1

Mean ± SE

1.4 × 10−10

5.8 × 10−6

2.2 × 10−8

2.9 × 10−10

3.6 × 10−5

6.3 × 10−6

9.8 × 10−5

2.7 × 10−14

P

0.64 ± 1.17

−14.29 ± 0.71

0.77 ± 0.72

−3.19 ± 0.39

2.21 ± 1.02

−4.53 ± 0.47

0.75 ± 0.81

−4.24 ± 0.45

−1.10 ± 2.30

−11.26 ± 1.28

9.38 ± 7.61

−36.39 ± 4.47

−0.004 ± 0.24

−1.06 ± 0.13

0.2 ± 0.2

−1.3 ± 0.1

Change from
baseline

1 Year

0.58

9.7 × 10−56

0.28

1.8 × 10−14

0.03

6.5 × 10−18

0.35

3.5 × 10−18

0.63

3.2 × 10−16

0.22

1.0 × 10−14

0.99

7.3 × 10−14

0.31

6.6 × 10−38

P

−9.73 ± 2.20

112.35 ± 1.90

102.62 ± 1.10

−2.74 ± 0.74

10.62 ± 0.64

7.88 ± 0.35

−3.01 ± 0.85

8.26 ± 0.75

5.25 ± 0.38

−4.67 ± 0.89

9.95 ± 0.77

5.27 ± 0.44

−8.15 ± 2.14

24.17 ± 1.84

16.02 ± 1.02

−38.31 ± 8.21

172.89 ± 7.00

134.58 ± 4.13

−0.73 ± 0.26

3.89 ± 0.22

3.16 ± 0.12

−1.2 ± 0.2

7.9 ± 0.2

6.7 ± 0.1

Mean ± SE

1.5 × 10−5

2.5 × 10−4

5.4 × 10−4

3.4 × 10−7

1.7 × 10−4

4.8 × 10−6

5.0 × 10−3

1.3 × 10−9

P

1.28 ± 1.63

−11.94 ± 0.96

−0.42 ± 0.70

−3.37 ± 0.39

−0.40 ± 0.94

−3.83 ± 0.49

0.37 ± 0.83

−3.82 ± 0.49

−3.40 ± 2.22

−11.71 ± 1.25

21.68 ± 8.28

−29.10 ± 4.88

−0.49 ± 0.24

−1.17 ± 0.13

0.4 ± 0.2

−0.9 ± 0.1

Change from
baseline

2 Years

(Continued)

0.43

8.8 × 10−28

0.55

1.1 × 10−15

0.68

2.7 × 10−13

0.66

3.8 × 10−13

0.13

2.2 × 10−18

0.01

6.8 × 10−9

0.04

2.2 × 10−16

0.02

1.8 × 10−17

P
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Mean ± SE

Baseline
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1.27 ± 0.02

5.89 ± 0.07

1.21 ± 0.01

18.74 ± 0.16

12

82.1 ± 1.0

−0.3 ± 1.1

Usual Care

CCI-all vs. usual care

81.3 ± 1.0

3.1 ± 1.6

197.2 ± 9.1

282.9 ± 45.1

−85.7 ± 30.1

CCI-all education

Usual Care

CCI-all vs. usual care

Triglycerides (mg/dL)b

38.7 ± 1.4

CCI-all vs. usual care

41.8 ± 0.9

3.6 ± 4.8

Usual Care

CCI-all education

HDL-cholesterol (mg/dL)

CCI-all vs. usual care

103.5 ± 2.2

100.0 ± 4.2

CCI-all education

Usual Care

0.09

0.06

0.46

−165.5 ± 39.0

314.5 ± 61.4

148.9 ± 10.1

12.4 ± 2.0

37.2 ± 1.7

49.5 ± 0.9

25.2 ± 5.6

88.9 ± 4.9

114.1 ± 2.5

13.5 ± 7.0

3.3 ± 5.7

LDL-cholesterol (mg/dL)

CCI-all vs. usual care

179.4 ± 6.1

184.4 ± 2.7

181.2 ± 4.9

192.8 ± 3.4

−3.2 ± 1.1

CCI-all education
0.57

0.76

78.1 ± 0.6

Usual Care

Total cholesterol (mg/dL)

81.8 ± 0.5

CCI-all education

−4.2 ± 1.8

129.5 ± 1.6

1.4 ± 1.8

130.3 ± 1.6

17.41 ± 0.15

1.18 ± 0.02

4.62 ± 0.08

1.22 ± 0.01

Mean ± SE

125.3 ± 0.9
0.43

—

—

—

—

P

131.7 ± 0.9

Diastolic blood pressure (mmHg)

CCI-all vs. usual care

Usual Care

CCI-all education

Systolic blood pressure (mmHg)

CARDIOVASCULAR

CCI-all education

Lower extremities lean mass (kg)

CCI-all education

Android: gynoid ratio

CCI-all education

Central abdominal fat (kg)

CCI-all education

Spine bone mineral density (g/cm2 )

TABLE 2 | Continued

1.5 × 10−8

1.1 × 10−9

8.9 × 10−6

0.06

0.41

0.02

—

—

—

—

P

31.6 ± 74.6

−48.3 ± 13.7

−1.5 ± 1.4

7.8 ± 0.8

−11.2 ± 4.7

10.6 ± 2.5

−1.8 ± 5.5

8.4 ± 3.1

−0.8 ± 1.1

−3.7 ± 0.7

−0.9 ± 1.9

−6.5 ± 1.1

−1.33 ± 0.10

−0.09 ± 0.1

−1.27 ± 0.07

0.01 ± 0.01

Change from
baseline

1 Year

0.35

7.4 × 10−16

0.3

4.4 × 10−19

0.02

2.5 × 10−5

0.75

0.01

0.47

5.4 × 10−8

0.66

3.3 × 10−8

5.9 × 10−31

2.4 × 10−13

1.3 × 10−42

0.11

P

−56.2 ± 19.0

209.5 ± 18.5

153.3 ± 10.4

7.1 ± 2.0

42.5 ± 1.7

49.5 ± 1.0

23.7 ± 5.9

90.9 ± 5.1

114.6 ± 2.8

13.3 ± 7.2

180.9 ± 6.2

194.1 ± 3.5

−2.8 ± 1.3

81.6 ± 1.1

78.7 ± 0.6

−3.9 ± 2.1

129.9 ± 1.8

125.9 ± 1.0

17.38 ± 0.17

1.20 ± 0.02

4.99 ± 0.10

1.22 ± 0.01

Mean ± SE

7.1 × 10−5

4.1x 10−4

7.0x 10−5

0.07

0.03

0.06

—

—

—

—

P

−73.4 ± 55.9

−43.9 ± 14.0

3.8 ± 1.6

7.8 ± 0.9

−9.1 ± 5.1

11.1 ± 2.8

−0.3 ± 6.4

9.7 ± 3.6

−0.6 ± 1.3

−3.1 ± 0.7

−0.5 ± 2.1

−5.8 ± 1.2

−1.36 ± 0.12

−0.07 ± 0.01

−0.90 ± 0.08

0.01 ± 0.01

Change from
baseline

2 Years

(Continued)

0.75

6.2 × 10−9

0.02

2.7 × 10−16

0.08

1.1x 10−4

0.96

0.01

0.65

3.3 × 10−5

0.83

2.4 × 10−6

1.3 × 10−21

4.7 × 10−8

1.6 × 10−21

0.02

P
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3.31 ± 1.99

CCI-all vs. usual care
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21.51 ± 1.13

0.99 ± 1.31

Usual Care

CCI-all vs. usual care

78.55 ± 2.53

−4.42 ± 2.94

Usual Care

CCI-all vs. usual care

13

0.09 ± 0.44

CCI-all vs. usual care

−0.09 ± 0.22

CCI-all vs. usual care

0.22 ± 0.65

CCI-all vs. usual care

CCI-all education

80.53 ± 0.78

16.18 ± 0.56

Usual Care

eGFR (mL s−1 m−2 )

16.40 ± 0.32

CCI-all education

BUN (mmol L−1 )a

6.83 ± 0.11

6.92 ± 0.19

CCI-all education

Usual Care

Anion gap (mmol L−1 )

KIDNEY

0.74

0.68

−0.19 ± 0.12

0.14 ± 0.13

82.50 ± 0.78

2.63 ± 0.74

15.83 ± 0.63

18.46 ± 0.37

−0.63 ± 0.25

7.74 ± 0.22

7.12 ± 0.13

−0.77 ± 0.14

−0.45 ± 0.11

Usual Care

CCI-all vs. usual care

−2.45 ± 0.40

3.79 ± 0.35

1.34 ± 0.19

−0.04 ± 0.03

0.57 ± 0.03

0.53 ± 0.02

−14.71 ± 2.97

79.05 ± 2.55

64.34 ± 1.44

−4.30 ± 1.17

23.37 ± 1.00

19.07 ± 0.58

−5.45 ± 1.77

26.98 ± 1.51

21.53 ± 0.88

Mean ± SE

−0.95 ± 0.07
0.27

0.83

0.64

0.13

0.45

0.1

P

−0.31 ± 0.06

CCI-all education

NAFLD-Fibrosis score

3.29 ± 0.21

3.20 ± 0.38

CCI-all education

Usual Care

NAFLD-Liver fat scorea

−0.01 ± 0.03

0.55 ± 0.02

Usual Care

CCI-all vs. usual care

0.53 ± 0.01

CCI-all education

Bilirubin (mg/dL)a

74.13 ± 1.42

CCI-all education

ALP (Units/L)

22.50 ± 0.64

CCI-all education

AST (Units/L)a

29.16 ± 0.97

25.84 ± 1.72

Usual Care

Mean ± SE

Baseline

CCI-all education

ALT (Units/L)a

LIVER

TABLE 2 | Continued

4.0 × 10−4

0.01

4.4 × 10−8

4.2 × 10−9

0.18

1.2 × 10−6

2.8 × 10−4

0.002

P

1.97 ± 0.67

−0.35 ± 0.61

2.06 ± 0.36

0.82 ± 0.25

0.29 ± 0.15

0.27 ± 0.12

−0.64 ± 0.06

0.59 ± 0.40

−1.95 ± 0.22

0.03 ± 0.02

−0.001 ± 0.01

0.50 ± 1.65

−9.78 ± 0.98

1.86 ± 1.19

−3.43 ± 0.69

1.14 ± 1.73

−7.63 ± 1.02

Change from
baseline

1 Year

0.004

0.57

3.8 × 10−8

0.001

0.05

0.01

4.0 × 10−22

0.14

2.0 × 10−16

0.16

0.92

0.76

1.9 × 10−20

0.12

1.1 × 10−6

0.51

7.7 × 10−13

P

83.26 ± 0.80

1.20 ± 0.90

16.21 ± 0.68

17.41 ± 0.40

−0.51 ± 0.25

7.80 ± 0.22

7.29 ± 0.13

−0.54 ± 0.16

−0.24 ± 0.14

−0.78 ± 0.08

−2.32 ± 0.43

3.02 ± 0.37

0.71 ± 0.20

0.01 ± 0.03

0.52 ± 0.03

0.52 ± 0.02

−17.97 ± 3.22

82.47 ± 2.76

64.50 ± 1.58

−3.41 ± 1.16

23.19 ± 0.99

19.78 ± 0.57

−3.80 ± 1.84

26.80 ± 1.57

23.00 ± 0.91

Mean ± SE

0.14

0.04

0.001

1.6 × 10−7

0.8

5.1 × 10−8

3.5 × 10−3

0.04

P

2.73 ± 0.72

0.03 ± 0.72

1.01 ± 0.43

0.88 ± 0.24

0.46 ± 0.14

0.21 ± 0.14

−0.47 ± 0.08

−0.17 ± 0.40

−2.58 ± 0.22

−0.03 ± 0.02

−0.01 ± 0.01

3.92 ± 2.00

−9.63 ± 1.19*

1.68 ± 1.14

−2.72 ± 0.66

0.96 ± 1.62

−6.16 ± 0.95

Change from
baseline

2 Years

(Continued)

1.6 × 10−4

0.97

0.02

3.2 × 10−4

0.003

0.12

2.3 × 10−9

0.66

2.9 × 10−25

15

0.45

0.05

1.8 × 10−14

0.14

5.1 × 10−5

0.56

4.0 × 10−10

P
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1.82 ± 1.61
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−0.02 ± 0.02

CCI-all vs. usual care

5.67 ± 0.16

0.16 ± 0.19

Usual Care

CCI-all vs. usual care

14

0.06 ± 0.02

CCI-all vs. usual care

9.03 ± 0.75

CCI-all education

White blood cell (k/cumm)

7.22 ± 0.12

−1.58 ± 0.87

Usual Care

CCI-all vs. usual care

7.45 ± 0.42

CCI-all education

hsC-reactive protein (nmol L−1 )a

0.07

0.17 ± 0.03

6.52 ± 0.13

−4.05 ± 0.94

9.06 ± 0.81

5.01 ± 0.46

0.10 ± 0.04

0.14 ± 0.02

0.03 ± 0.02

Usual Care

CCI-all vs. usual care

0.03 ± 0.03

0.89 ± 0.02

0.92 ± 0.01

−0.04 ± 0.15

1.92 ± 0.13

1.89 ± 0.07

0.39 ± 0.21

5.44 ± 0.18

5.82 ± 0.10

−0.04 ± 0.02

0.87 ± 0.02

0.83 ± 0.01

2.94 ± 1.59

79.56 ± 1.36

Mean ± SE

0.27 ± 0.02
0.11

0.003

0.15

0.39

0.37

0.26

P

0.18 ± 0.01

CCI-all education

Beta-hydroxybutyrate (mmol L−1 )a

Other

0.91 ± 0.01

0.85 ± 0.02

CCI-all education

Usual Care

Free T4 (pmol L−1 )a

0.23 ± 0.16

1.94 ± 0.14

Usual Care

CCI-all vs. usual care

2.16 ± 0.08

CCI-all education

TSH (mIU L−1 )a

THYROID

5.83 ± 0.09

CCI-all education

Uric acid (µmo L−1 )

0.88 ± 0.01

0.90 ± 0.02

CCI-all education

Usual Care

Serum creatinine (µmol L−1 )a

78.70 ± 1.39

CCI-all vs. usual care

Mean ± SE

Baseline

Usual Care

TABLE 2 | Continued

2.1 × 10−5

0.01

0.23

0.79

0.06

0.12

0.07

P

−0.70 ± 0.10

0.03 ± 0.69

−2.44 ± 0.40

0.03 ± 0.03

0.09 ± 0.02

0.04 ± 0.02

0.01 ± 0.01

−0.01 ± 0.12

−0.28 ± 0.07*

−0.24 ± 0.14

−0.01 ± 0.08

−0.03 ± 0.02

−0.04 ± 0.01

0.86 ± 1.13

Change from
baseline

1 Year

6.6 × 10−11

0.96

2.4 × 10−9

0.43

6.8 × 10−7

0.53

0.04

0.92

1.3 × 10−4

0.09

0.9

0.07

5.3 × 10−6

0.45

P

6.68 ± 0.15

−3.69 ± 0.86

8.38 ± 0.74

4.69 ± 0.40

0.09 ± 0.04

0.18 ± 0.04

0.27 ± 0.02

0.02 ± 0.03

0.90 ± 0.02

0.93 ± 0.01

−0.10 ± 0.16

2.04 ± 0.14

1.90 ± 0.08

0.59 ± 0.21

5.13 ± 0.18

5.72 ± 0.10

−0.04 ± 0.02

0.88 ± 0.02

0.85 ± 0.01

4.14 ± 1.63

79.12 ± 1.39

Mean ± SE

2.3 × 10−5

0.03

0.34

0.52

0.005

0.12

0.01

P

−0.54 ± 0.13

−0.65 ± 0.65

−2.76 ± 0.37

0.03 ± 0.04

0.09 ± 0.02

0.05 ± 0.02

0.01 ± 0.01

0.11 ± 0.16

−0.22 ± 0.09

−0.54 ± 0.16

−0.11 ± 0.09

−0.01 ± 0.02

−0.03 ± 0.01

0.42 ± 1.21

Change from
baseline

2 Years

(Continued)

4.3 × 10−5

0.32

6.9 × 10−13

0.38

4.7 × 10−5

0.25

0.01

0.49

0.01

6.2 × 10−4

0.2

0.39

0.003

0.73

P
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8.12 ± 0.22

−0.90 ± 0.26

Usual Care

CCI-all vs. usual care

Ns for continuous care intervention = 262 and Ns for usual care = 87. Unless otherwise noted, estimates reported were obtained from linear mixed-effects models which provide adjusted means and mean changes, controlling for
baseline age, sex, race, body mass index, and insulin use. This maximum likelihood-based approach uses all available repeated data, resulting in an intent-to-treat analysis. A significance level of P < 0.0012 ensures overall simultaneous
significance of P < 0.05 over the 43 variables using Bonferroni correction. Abbreviations: SE, standard error; CCI, continuous care intervention; UC, usual care; HOMA-IR, homeostatic model assessment of insulin resistance; LDL,
low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; NAFLD, nonalcoholic fatty liver disease; BUN, blood urea nitrogen; eGFR, estimated
glomerular filtration rates; TSH, thyroid stimulating hormone.
a Variable was positively skewed and after removing the top 1% of values, skew and kurtosis values fell within acceptable ranges. Analyses were conducted on data excluding the top 1% of values for each variable, although due to the
maximum likelihood approach all cases were still included in the analyses.
b Variable was positively skewed and a natural log transformation was performed. The linear mixed-effects model analysis including covariates was conducted on the transformed variable and significance values provided are from the
transformed analysis. However, because transformed numbers are difficult to interpret, non-transformed and unadjusted means, mean changes, and standard errors for participants who completed the study visit were computed and
provided in the table.

0.82
−0.05 ± 0.23
8.07 ± 0.27
0.82
2.3 × 10−9
5.3 × 10−4

8.16 ± 0.23

−1.64 ± 0.27*

0.04 ± 0.17

Mean ± SE
P
Change from
baseline
P
Mean ± SE
Mean ± SE

P

1 Year
Baseline
TABLE 2 | Continued

−1.39 ± 0.32

1.6 × 10−5

P
Change from
baseline

Carbohydrate Restriction and Type 2 Diabetes

P

2 Years
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conducted, all below ns = 262) and Supplementary Table 5
(per-protocol analyses). At 2 years, 27.2% of CCI participants
(P = 4.9 × 10−15 ) and 6.5% of UC patients showed resolution
of metabolic syndrome. The proportion of CCI patients with
suspected steatosis was reduced from 95.8 to 67.4% (P < 0.0
× 10−36 ), whereas no change occurred in UC at 2 years. The
proportion of patients without suspected fibrosis increased from
18.3 to 30.8% (P = 1.4 × 10−5 ) in the CCI, but did not change in
the UC at 2 years.

Adverse Events
In the CCI group, there were no reported adverse events
between 1 and 2 years related to the intervention or that
resulted in discontinuation, including no reported episodes
of ketoacidosis or severe hypoglycemia requiring assistance.
Limited or no change in kidney and thyroid functions were
seen in the CCI at 2 years. Adverse events occurring in the
first year of intervention (n = 6) were previously reported (11);
during the second year of intervention, nine adverse events were
reported including: one breast cancer diagnosis, one mycosis
fungoides, one onset of atrial fibrillation (Afib) with heart
failure, one onset of migraine, two cases of chest pain (one
resulting in stent placement), one pulmonary effusion, and two
pulmonary embolisms (one following orthopedic surgery and
one with benign ovarian mass/Afib) in the CCI group. In the
UC group, adverse events occurring in the first year (n = 6)
were previously reported (11), and in the second year, adverse
events occurred in six participants: one death from liver cancer,
one hospitalization from recurrent seizure, one ureteropelvic
junction obstruction from kidney stone, one cerebrovascular
accident with left side weakness and sensory disturbances, one
chest pain requiring percutaneous coronary intervention, and
one deep vein thrombosis.

DISCUSSION
Following 2 years of a remote continuous care intervention
supporting medical and lifestyle changes, the CCI participants
demonstrated improved HbA1c, fasting glucose and insulin,
and HOMA-IR. Pharmaceutical interventions of 1.5 to 3 years
duration report HbA1c reductions of 0.2 to 1.0% with DPP4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).
The HbA1c reduction of 0.9% with this CCI is comparable to
that observed in pharmaceutical trials, but is achieved while
discontinuing 67.0% of diabetes-specific prescriptions including
most insulins and all sulfonylureas that engender risks for weight
gain and hypoglycemia (50, 51). Comparable improvements in
glycemic control and reduced medication were not observed
in UC participants recruited from the same healthcare system,
suggesting that the CCI improves diabetes management relative
to usual care. Other interventions using carbohydrate restriction
reported variable long-term glycemic improvement outcomes
(52–57). The 0.9% absolute (12% relative) HbA1c reduction
observed at 2 years is consistent with low carbohydrate studies
reporting HbA1c reductions of 8–15% at 2 to 3.5 years (52, 55–
57) with medication reduction. Two other studies reported no

15
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FIGURE 2 | Adjusted mean changes from baseline to 2 years in the CCI group for (A) HbA1c (−12% relative to baseline, P = 1.8×10−17 ), (B) Fasting insulin (−42%
relative to baseline, P = 2.2 × 10−18 ).

FIGURE 3 | Medication and insulin dose changes from baseline to 2 years for CCI and UC group completers. (A) Percent of completers taking diabetes medications,
excluding metformin. (B) Mean ± SE prescribed insulin dose among baseline users. (C) Frequency of medication dosage and use change among prescribed users by
diabetes medication class.

changes in HbA1c from baseline to 2 years, even though the lowcarbohydrate arm reduced HbA1c in the first 6 months (53, 54).
Criticisms of low-carbohydrate diets relate to poor adherence
and long-term sustainability (25, 26, 28). In this CCI, selfmonitoring combined with continuous remote-monitoring and
feedback from the care team, including behavioral support and
nutrition advice via the app, may have improved accountability
and engagement (58). In addition to glucose and weight tracking,
dietary adherence was monitored by blood ketones. The 2 year
BHB increase above baseline demonstrates sustained dietary
modification. While laboratory BHB levels were increased from
baseline, the encouraged range of nutritional ketosis (≥0.5 mM)
was observed in only a minority (14.1%) of participants at 2 years.

Frontiers in Endocrinology | www.frontiersin.org

On average, patient-measured BHB was ≥0.5 mM for 32.8% of
measurements over the 2 years (Supplementary Figure 4).
This reveals an opportunity to increase adherence
to nutritional ketosis for patients not achieving their
desired health outcomes while prompting future research
investigating the association between dietary adherence and
health improvements.
A majority of the CCI participants (53.5%) met criteria
for diabetes reversal at 2 years while 17.6% achieved diabetes
remission (i.e., glycemic control without medication use) based
on intent-to-treat with multiple imputation. The percentage
of all CCI enrollees (N = 262) with verified reversal and
remission requiring both completion of 2 years of the trial
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FIGURE 4 | Adjusted mean changes from baseline to 2-years in the CCI group for (A) Weight (−10% relative to baseline, P = 8.8 × 10−28 ), (B) Central Abdominal
Fat [CAF] (−15% relative to baseline, P = 1.6 × 10−21 ), (C) Systolic Blood Pressure (−4% relative to baseline, P = 2.4 × 10−6 ), (D) Diastolic Blood Pressure (−4%
relative to baseline, P = 3.3 × 10−5 ) (E) Alanine aminotransferase [ALT] (−21% relative to baseline, P = 4.0 × 10−10 ), and (F) High sensitive C-reactive protein
[hsCRP](−37% relative to baseline, P = 6.9 × 10−13 ).

the Look AHEAD trial (9.2%) (5). Greater diabetes remission
in the CCI vs. Look AHEAD ILI could result from differences
in the dietary intervention (23), patients’ ability to self-select
their lifestyle change or effectiveness of continuous remote care.
Length of time with a T2D diagnosis is a factor in remission, with
longer time since diagnosis resulting in lower remission (4, 5, 9).
Despite a mean and median of 8.4 and 7 years since diagnosis
among CCI participants, the remission rate was higher than the
Look AHEAD trial where its participants had a median of 5 years
(4) since diabetes diagnosis.

and an obtained laboratory value for HbA1c were 37.8 and
14.9%, respectively. CCI diabetes reversal exceeds remission as
prescriptions for metformin were usually continued given its
role in preventing disease progression (10, 59), preserving β-cell
function (59) and in the treatment of pre-diabetes per guidelines
(28). Partial and complete remission rates of 2.4 and 0.2%
per year, respectively, were reported in 122,781 T2D patients
receiving standard diabetes care (4). The 2 year remission rate
(both partial and complete) in the CCI (17.6%) is higher than
that achieved through intensive lifestyle intervention (ILI) in
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and children could be due to differential effects on developed
and mineralized vs. developing bones (84). In this study, the CCI
group had a reduction (7.0%, 1.3 kg) in the calculated LELM.
Most lean mass loss was encountered in the first year without
further reduction in year 2. Studies have reported that obese
adults have about 20% higher thigh muscle mass than those
with normal weight (85). The reduced upper body load burden
achieved through weight loss might explain the reduction of
LELM. This reflects an appropriate weight loss-related reduction
in muscle mass rather than muscle deficiency (86, 87). Weight
loss (∼10%) induced by energy restriction resulted in slightly
higher lean mass loss than the CCI (8.4% appendicular lean mass
and 7.6% total lean mass loss at 20 weeks) (88). Total lean mass
loss from 10% weight reduction by bariatric surgery is reported in
the range of 7.3 to 15.9% from baseline (89, 90). Greater weight
is associated with more lean mass loss (91, 92). Approximately
25% of diet-induced weight loss (without exercise) often arises
from lean mass (93). In the present intervention, lean mass loss
contributed an estimated 14% to the lower extremity weight loss.
The lower proportion of lean mass loss in the CCI group, despite
higher percentage of weight loss, may be due to the adequate
dietary protein recommendations (94, 95). Since ∼73% of lean
mass is water, the observed reduction of LELM in the first year of
intervention may have arisen from natriuresis and water loss that
occurs during keto-adaptation (96, 97).

Participants in the CCI achieved 10% mean weight loss
(−11.9 kg) at 2 years. CCI weight loss was comparable
to observed weight loss following surgical gastric banding
(−10.7 kg) at 2 years (59). Previous studies consistently report
that weight loss increases the likelihood of T2D remission (4, 5,
9). CCI participants also improved blood pressure, triglycerides,
and HDL-cholesterol. Total cholesterol was unchanged and LDLcholesterol was increased at 2 years, but was not different from
the LDL-cholesterol level observed at 1 year (+0.51 mg/dL, P
= 0.85). Despite the rise in LDL-cholesterol, the CCI cohort
improved in 22 out of 26 CVD markers at 1 year (33). These
changes included a decrease in small LDL-particles and large
VLDL-P and an increase in LDL-particle size partitioning with
no changes in ApoB (33), a marker considered a better predictor
of CVD risk than LDL-cholesterol (33, 60). Non-elevated
LDL cholesterol values together with higher triglycerides and
lower HDL-cholesterol are common in patients with abdominal
obesity, T2D, and metabolic syndrome (61, 62); these individuals
often still have elevated atherogenic lipoproteins such as nonHDL (63), small LDL particles (62, 64), and VLDL (62, 64). In the
CCI group, non-HDL cholesterol did not change from baseline to
2 years (141.7 ± 2.6 at baseline to 143.7 ± 3.1 mg/dl, P = 0.51)
and several cardiovascular risk factors improved, suggesting that
the rise in LDL-cholesterol may not be associated with increased
atherogenic risk (65).
The CCI group had a reduction in visceral fat content, CAF
and A/G ratio. This is consistent with other low-carbohydrate
interventions reporting visceral fat reduction as a component of
weight loss (30, 56, 66–68). Anatomical distribution of fat around
the abdominal area (“android” obesity) is associated with T2D
(69) and other comorbidities such as metabolic syndrome (70)
and NAFLD (71). The alleviation of visceral fat in the CCI group
was concurrent with resolution of metabolic syndrome at 2 years,
while sustaining 1 year improvements of liver enzymes (10),
steatosis, and fibrosis (72). The comprehensive effect of reduced
visceral fat and improvement in associated comorbidities was
previously reported (68, 73, 74). Rat studies have shown that
removal of visceral adipose tissue increases insulin sensitivity
while delaying T2D (75), and prevents metabolic syndrome
and NAFLD (76). Resolution of liver steatosis and fibrosis may
protect against other T2D macrovascular and microvascular
complications such as cardiovascular disease and nephropathy
(77). Furthermore, abdominal adiposity and NAFLD are
frequently associated with altered inflammatory pathways in
T2D patients (71). Excess free fatty acids from visceral adipose
tissue may initiate chronic low-grade inflammation and activate
nuclear factor kappa B signaling (71, 77). CCI participants also
improved inflammatory status (hsCRP and WBC) at 1 year (10)
and 2 years.
While some studies in animal models (78, 79) and children
treated with ketogenic diets (80, 81) have suggested retardation
in skeletal development and reduction in BMD, in this study of
adults with T2D the CCI group had no change in total spine BMD
over 2 years. Our results are consistent with other adult ketogenic
dietary studies that reported no bone mass loss in short-term
(66) or long-term follow-up of 2 (67, 82) and 5 (83) years. The
differing findings of ketogenic diet on bone mass between adults
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Strengths and Limitations
This study’s strengths include its size and prospective,
longitudinal data collection from two participant groups
(CCI and UC) which allowed statistical analysis by linear mixed
effects model to investigate intervention time and treatment
effects. The UC group was prospectively recruited from the same
healthcare system. While not randomized, the participants’ selfselection of intervention may contribute to the observed high
retention and predicts real-life clinical management of chronic
disease. The study also included patients prescribed insulin
and with long-standing disease, groups often excluded from
prior studies. The multi-component aspect of the intervention
involving regular biomarker monitoring and access to a remote
care team may have improved the long-term dietary adherence
and engagement. The dietary advice including encouraging
participants to restrict carbohydrates, moderate protein intake,
and eat to satiety may also help in maintaining long-term
effectiveness. Weaknesses of this study include the lack of
randomization and racial diversity limiting generalization of
the results to all T2D patients. Interpretation of DXA body
composition was limited to subregion analyses due to the
scanner not accommodating the patients’ complete body.

CONCLUSIONS
At 2 years, the CCI, including remote medical management
with instruction in nutritional ketosis, was associated with
improvements in blood glucose, insulin, HbA1c, weight, blood
pressure, triglyceride, liver function, and inflammation and
reduced dependence upon medication. These long-term benefits
were achieved concurrent with reduced prevalence of metabolic
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syndrome, and visceral adiposity. The CCI had no adverse
effect on bone mineral density. The CCI group also had a
higher prevalence of diabetes reversal and remission compared
to the UC group following a standard diabetes care program.
These results provide evidence that sustained improvement in
diabetes status can be achieved through the continuous remote
monitoring and accountability mechanisms provided by this
multi-component CCI including recommendations for lowcarbohydrate nutrition.
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